AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1911501 — intervention group
Group type: COMPARATOR
Intervention: 2.6-mg MS bolus and subsequent MS infusion at 0.1 mg/hour (n = 18)
Number of subjects: 31
Study 7036092 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting secretin in doses of 10 clinical units twice daily
Number of subjects: 100
Study 31982847 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP maintained from baseline to 10% above the baseline (group H)
Number of subjects: 150
Study 31982847 — intervention group
Group type: COMPARATOR
Intervention: MAP maintained from 10% to 20% below the baseline (group D)
Number of subjects: 150
Study 31982847 — intervention group
Group type: COMPARATOR
Intervention: MAP maintained from baseline to 10% below the baseline (group M)
Number of subjects: 150
Study 30896643 — intervention group
Group type: EXPERIMENTAL
Intervention: Allisartan isoproxil
Number of subjects: 80
Study 30896643 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 80
Study 29140929 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute nociceptive low back pain induced by saline injection
Number of subjects: 0
Study 29140929 — intervention group
Group type: COMPARATOR
Intervention: Sham injection (nocebo pain)
Number of subjects: 0
Study 29140929 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0
Study 25524125 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 120
Study 25524125 — intervention group
Group type: COMPARATOR
Intervention: Dermal patch (control)
Number of subjects: 120
Study 23695501 — intervention group
Group type: EXPERIMENTAL
Intervention: FACETS plus current local practice (FACETS)
Number of subjects: 164
Study 23695501 — intervention group
Group type: COMPARATOR
Intervention: Current local practice alone (CLP)
Number of subjects: 164
Study 21872244 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 μg of oral misoprostol
Number of subjects: 242
Study 21872244 — intervention group
Group type: COMPARATOR
Intervention: Manual vacuum aspiration (MVA)
Number of subjects: 242
Study 19485583 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervisor focus on adherence to treatment principles
Number of subjects: 1979
Study 19485583 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to the Structure and Process of Supervision
Number of subjects: 1979
Study 19485583 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus on Clinician Development
Number of subjects: 1979
Study 17214933 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese herbal medicine (CM) including Glucosidorum Tripterygii Totorum Tablet and syndrome differentiation treatment
Number of subjects: 397
Study 17214933 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (WM) including voltaren extended action tablet, methotrexate, and sulfasalazine
Number of subjects: 397
Study 17214933 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural network model analysis
Number of subjects: 397
Study 15266634 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-mA bipolar, binaural galvanic vestibular stimulation (GVS) triggered prior to plantarflexor activity
Number of subjects: 0
Study 15266634 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GVS)
Number of subjects: 0
Study 11319627 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Ma Huang/Guarana (72 mg/day ephedrine alkaloids and 240 mg/day caffeine)
Number of subjects: 67
Study 11319627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 11319627 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Ma Huang/Guarana
Number of subjects: 67
Study 9595179 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-management training (education, relaxation, and problem-solving training)
Number of subjects: 43
Study 9595179 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 43
Study 9595179 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-management training (self-measured BP)
Number of subjects: 43
Study 9595179 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-management training (4-month follow-up)
Number of subjects: 43
Study 7636666 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole suspension, 2 to 3 mg/kg per day
Number of subjects: 182
Study 7636666 — intervention group
Group type: COMPARATOR
Intervention: Nystatin, 400,000 units four times daily for 14 days
Number of subjects: 182
Study 2794994 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide 600 mg/d
Number of subjects: 75
Study 2794994 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine 200 mg/d
Number of subjects: 75
Study 2794994 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 caps/d)
Number of subjects: 75
Study 991103 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent combination chemotherapy with cyclophosphamide, methotrexate, and 5-fluourouracil (CMF)
Number of subjects: 184
Study 991103 — intervention group
Group type: COMPARATOR
Intervention: L-phenylalanine mustard (L-PAM)
Number of subjects: 184
Study 991103 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF
Number of subjects: 184
Study 30998121 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% albumin
Number of subjects: 6
Study 30998121 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 6
Study 30998121 — intervention group
Group type: COMPARATOR
Intervention: Hartmann's solution
Number of subjects: 6
Study 30998121 — intervention group
Group type: COMPARATOR
Intervention: 4% albumin
Number of subjects: 6
Study 30998121 — intervention group
Group type: COMPARATOR
Intervention: 30 ml/kg of 0.9% saline, Hartmann's solution, and 4% albumin
Number of subjects: 6
Study 30998121 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloids (including 20% albumin)
Number of subjects: 6
Study 25726942 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraprocedural thrombotic events (IPTE)
Number of subjects: 1307
Study 22936724 — intervention group
Group type: EXPERIMENTAL
Intervention: Anabolic steroids
Number of subjects: 0
Study 22936724 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoids
Number of subjects: 0
Study 22936724 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-I stimulation
Number of subjects: 0
Study 20884100 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterols (PS)
Number of subjects: 67
Study 19083472 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (WY) 15 g
Number of subjects: 15
Study 19083472 — intervention group
Group type: COMPARATOR
Intervention: Essential amino acids (EAA) 6.72 g
Number of subjects: 15
Study 19083472 — intervention group
Group type: COMPARATOR
Intervention: Nonessential amino acids (NEAA) 7.57 g
Number of subjects: 15
Study 16510062 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical allylamine antifungals (naftifine, terbinafine, butenafine)
Number of subjects: 0
Study 16510062 — intervention group
Group type: COMPARATOR
Intervention: Topical azole antifungals (clotrimazole, econazole, ketoconazole, oxiconazole, miconazole, sulconazole)
Number of subjects: 0
Study 14765003 — intervention group
Group type: EXPERIMENTAL
Intervention: OCD participants
Number of subjects: 0
Study 14765003 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study 14765003 — intervention group
Group type: EXPERIMENTAL
Intervention: Both patients and controls
Number of subjects: 0
Study 10894274 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine therapy for 44-52 weeks
Number of subjects: 13
Study 8823239 — intervention group
Group type: EXPERIMENTAL
Intervention: Dezocine (7.5 to 60 mg)
Number of subjects: 6
Study 8823239 — intervention group
Group type: COMPARATOR
Intervention: Naloxone (0.1 and 0.2 mg)
Number of subjects: 6
Study 8823239 — intervention group
Group type: COMPARATOR
Intervention: Hydromorphone (5 and 10 mg)
Number of subjects: 6
Study 8823239 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 6
Study 1294638 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 18
Study 1294638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 6466933 — intervention group
Group type: EXPERIMENTAL
Intervention: 3' protocol with incline increments of 1.5%
Number of subjects: 10
Study 6466933 — intervention group
Group type: COMPARATOR
Intervention: Other treadmill protocols (motorised and non-motorised)
Number of subjects: 10
Study 28841028 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hospital ticagrelor treatment
Number of subjects: 1456
Study 28841028 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete ST-segment resolution post-percutaneous coronary intervention
Number of subjects: 1456
Study 28841028 — intervention group
Group type: EXPERIMENTAL
Intervention: Time from symptoms to pre-hospital electrocardiogram
Number of subjects: 1456
Study 28841028 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 1456
Study 28969431 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-DNA 600 μg (n=10)
Number of subjects: 24
Study 28969431 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-DNA 1200 μg (n=10)
Number of subjects: 24
Study 28969431 — intervention group
Group type: COMPARATOR
Intervention: Placebo saline injections (n=4)
Number of subjects: 24
Study 28969431 — intervention group
Group type: EXPERIMENTAL
Intervention: After first HIV-MVA boost
Number of subjects: 24
Study 28969431 — intervention group
Group type: EXPERIMENTAL
Intervention: After second HIV-MVA boost
Number of subjects: 24
Study 28969431 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-DNA vaccine (both doses)
Number of subjects: 24
Study 27861335 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic saline infusion (2L over 4 hours)
Number of subjects: 57
Study 27861335 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEi + Regular Sodium (RS) diet
Number of subjects: 57
Study 27861335 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on Hydrochlorothiazide (HCT)
Number of subjects: 57
Study 27861335 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Sodium (LS) diet
Number of subjects: 57
Study 27861335 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of HCT and LS diet
Number of subjects: 57
Study 27861335 — intervention group
Group type: COMPARATOR
Intervention: ACEi + RS treatment
Number of subjects: 57
Study 24295662 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection
Number of subjects: 0
Study 24295662 — intervention group
Group type: COMPARATOR
Intervention: Combined modality using chemotherapy and concurrent radiation
Number of subjects: 0
Study 23154315 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio computer-assisted self interview
Number of subjects: 4049
Study 23154315 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face interview
Number of subjects: 4049
Study 23154315 — intervention group
Group type: COMPARATOR
Intervention: Self-administered paper interview
Number of subjects: 4049
Study 21240149 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 36
Study 21240149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 17596121 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (3.7 g of n‐3 long‐chain PUFAs/day)
Number of subjects: 98
Study 17596121 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplement
Number of subjects: 98
Study 17596121 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 98
Study 16305004 — intervention group
Group type: EXPERIMENTAL
Intervention: CaviStat-containing dentifrice
Number of subjects: 726
Study 16305004 — intervention group
Group type: COMPARATOR
Intervention: Fluoride toothpaste (control)
Number of subjects: 726
Study 11966630 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback (group A, 28 men)
Number of subjects: 42
Study 11966630 — intervention group
Group type: COMPARATOR
Intervention: Verbal instructions (group B, 14 men)
Number of subjects: 42
Study 11966630 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 42
Study 10326116 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg twice daily of nitazoxanide
Number of subjects: 66
Study 10326116 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg twice daily of nitazoxanide
Number of subjects: 66
Study 10326116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 7704961 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) 4 mg orally
Number of subjects: 6
Study 7704961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2145744 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue-type plasminogen activator (rt-PA)
Number of subjects: 30
Study 2145744 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (no thrombolytic therapy)
Number of subjects: 30
Study 388398 — intervention group
Group type: EXPERIMENTAL
Intervention: tienilic acid
Number of subjects: 675
Study 388398 — intervention group
Group type: COMPARATOR
Intervention: hydrochlorothiazide
Number of subjects: 675
Study 388398 — intervention group
Group type: COMPARATOR
Intervention: probenecid
Number of subjects: 675
Study 388398 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 675
Study 30285506 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-pulsed intense pulsed light (IPL)
Number of subjects: 9
Study 30285506 — intervention group
Group type: COMPARATOR
Intervention: Pulsed dye laser (PDL)
Number of subjects: 9
Study 28063938 — intervention group
Group type: EXPERIMENTAL
Intervention: BCV 100 mg (2 mg/kg if <50 kg) twice weekly (BIW)
Number of subjects: 48
Study 28063938 — intervention group
Group type: EXPERIMENTAL
Intervention: BCV 200 mg (4 mg/kg if <50 kg) once weekly (QW)
Number of subjects: 48
Study 28063938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 28063938 — intervention group
Group type: EXPERIMENTAL
Intervention: BCV BIW
Number of subjects: 48
Study 28063938 — intervention group
Group type: EXPERIMENTAL
Intervention: BCV QW
Number of subjects: 48
Study 28063938 — intervention group
Group type: EXPERIMENTAL
Intervention: BCV BIW (post hoc analysis)
Number of subjects: 48
Study 28063938 — intervention group
Group type: COMPARATOR
Intervention: Placebo (post hoc analysis)
Number of subjects: 48
Study 25962930 — intervention group
Group type: EXPERIMENTAL
Intervention: Trophic breast milk feeds (10 mL/kg/day)
Number of subjects: 27
Study 25962930 — intervention group
Group type: COMPARATOR
Intervention: Nil per os (NPO)
Number of subjects: 27
Study 23810841 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (1400 IU and 14,000 IU)
Number of subjects: 338
Study 23810841 — intervention group
Group type: COMPARATOR
Intervention: Placebo oil
Number of subjects: 338
Study 21906798 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial programme (Weight Watchers)
Number of subjects: 772
Study 21906798 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 772
Study 19706085 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide 0.01% oil applied twice daily for 4 weeks
Number of subjects: 32
Study 19706085 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide 0.01% oil
Number of subjects: 32
Study 16900233 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n = 21) trained on a bicycle ergometer 4 times/week, 1 h/session, at 80% of their physical working capacity for 8 weeks.
Number of subjects: 38
Study 15039494 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab plus methotrexate
Number of subjects: 0
Study 15039494 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus methotrexate
Number of subjects: 0
Study 11731186 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated estrogens (0.625 mg)/micronised progesterone (200 mg)
Number of subjects: 37
Study 11731186 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg)
Number of subjects: 37
Study 11731186 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined interventions (HRT + Pravastatin)
Number of subjects: 37
Study 11731186 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 37
Study 9159675 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal incision (1.0 mm behind the surgical limbus)
Number of subjects: 180
Study 9159675 — intervention group
Group type: EXPERIMENTAL
Intervention: Incision at the 12 o'clock position
Number of subjects: 180
Study 9159675 — intervention group
Group type: EXPERIMENTAL
Intervention: Limbal incision at the 12 o'clock position
Number of subjects: 180
Study 9159675 — intervention group
Group type: EXPERIMENTAL
Intervention: Incision depth of 500 microns
Number of subjects: 180
Study 9159675 — intervention group
Group type: EXPERIMENTAL
Intervention: Incision depth of 300 microns
Number of subjects: 180
Study 9159675 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal scleral incisions
Number of subjects: 180
Study 9159675 — intervention group
Group type: EXPERIMENTAL
Intervention: Limbal incisions at the 12 o'clock position
Number of subjects: 180
Study 7805700 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam beta‐cyclodextrin
Number of subjects: 0
Study 7805700 — intervention group
Group type: COMPARATOR
Intervention: Plain piroxicam
Number of subjects: 0
Study 7805700 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam beta‐cyclodextrin sachets
Number of subjects: 0
Study 7805700 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam beta‐cyclodextrin (tablet and sachet formulations)
Number of subjects: 0
Study 3815764 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine (6 g for 7 days)
Number of subjects: 19
Study 3815764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 29191815 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural intervention to reduce STI incidence
Number of subjects: 330
Study 27640303 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes self-management education (DSME)
Number of subjects: 85
Study 27640303 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 85
Study 25682463 — intervention group
Group type: EXPERIMENTAL
Intervention: Free gingival graft
Number of subjects: 10
Study 25682463 — intervention group
Group type: COMPARATOR
Intervention: Control (spontaneous healing)
Number of subjects: 10
Study 22828945 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant
Number of subjects: 37
Study 22828945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 22828945 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric diet
Number of subjects: 37
Study 20850152 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexaminolevulinate fluorescence cystoscopy
Number of subjects: 814
Study 20850152 — intervention group
Group type: COMPARATOR
Intervention: White light cystoscopy
Number of subjects: 814
Study 18515890 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) plus treatment as usual
Number of subjects: 301
Study 18515890 — intervention group
Group type: EXPERIMENTAL
Intervention: Family intervention plus treatment as usual
Number of subjects: 301
Study 18515890 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 301
Study 15893181 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 3745
Study 15893181 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 40 mg
Number of subjects: 3745
Study 12668787 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined inhalation of nitric oxide and oxygen
Number of subjects: 40
Study 12668787 — intervention group
Group type: COMPARATOR
Intervention: Oxygen alone
Number of subjects: 40
Study 10697255 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergy Control Covers (ACC)
Number of subjects: 24
Study 10697255 — intervention group
Group type: EXPERIMENTAL
Intervention: High Efficiency Particulate Filters (HEPA)
Number of subjects: 24
Study 10697255 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 7548496 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (250 mg once a day for 3 days)
Number of subjects: 202
Study 7548496 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline (500 mg four times a day for 3 days)
Number of subjects: 202
Study 1940257 — intervention group
Group type: EXPERIMENTAL
Intervention: Silibinin 100 mg/kg body weight i.p. for 7 days
Number of subjects: 69
Study 1940257 — intervention group
Group type: EXPERIMENTAL
Intervention: Silibinin 50 mg/kg body weight i.p. for 7 days
Number of subjects: 69
Study 1940257 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin 420 mg per day for 30 days
Number of subjects: 69
Study 1940257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 7282067 — intervention group
Group type: EXPERIMENTAL
Intervention: penicillin and streptomycin
Number of subjects: 60
Study 7282067 — intervention group
Group type: COMPARATOR
Intervention: clindamycin and gentamycin
Number of subjects: 60
Study 30126064 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission cardiotocography (ACTG)
Number of subjects: 3034
Study 30126064 — intervention group
Group type: COMPARATOR
Intervention: Intermittent auscultation (IA)
Number of subjects: 3034
Study 28106354 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (20 mL of 0.5%) + Dexmedetomidine (1 µg/kg)
Number of subjects: 60
Study 28106354 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine (20 mL of 0.5%)
Number of subjects: 60
Study 25582310 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure™ Small Jaw (LSJ)
Number of subjects: 190
Study 25582310 — intervention group
Group type: COMPARATOR
Intervention: Clamp-and-tie (CT)
Number of subjects: 190
Study 25582310 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LSJ and CT
Number of subjects: 190
Study 24016068 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise and carrying rs1042718 minor allele
Number of subjects: 877
Study 24016068 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise and carrying rs1042718 or rs1042719 minor allele
Number of subjects: 877
Study 24016068 — intervention group
Group type: EXPERIMENTAL
Intervention: Social-leisure activities and carrying rs1042719 minor allele
Number of subjects: 877
Study 24016068 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrying rs1042718 or rs1042719 minor alleles
Number of subjects: 877